Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach

McGrath, 2008, Schizophrenia: a concise overview of incidence, prevalence, and mortality, Epidemiol Rev, 30, 67, 10.1093/epirev/mxn001 Leucht, 2013, Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis, Lancet, 382, 951, 10.1016/S0140-6736(13)60733-3 Higashi, 2013, Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review, Ther Adv Psychopharmacol, 3, 200, 10.1177/2045125312474019 2014, Biological insights from 108 schizophrenia-associated genetic loci, Nature, 511, 421, 10.1038/nature13595 Purcell, 2014, A polygenic burden of rare disruptive mutations in schizophrenia, Nature, 506, 185, 10.1038/nature12975 Kathiresan, 2008, Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans, Nat Gen, 40, 189, 10.1038/ng.75 Teslovich, 2010, Biological, clinical and population relevance of 95 loci for blood lipids, Nature, 466, 707, 10.1038/nature09270 Garcia-Calvo, 2005, The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1), Proc Natl Acad Sci USA, 102, 8132, 10.1073/pnas.0500269102 Haas, 2012, DGAT1 mutation is linked to a congenital diarrheal disorder, J Clin Invest, 122, 4680, 10.1172/JCI64873 Denison, 2014, Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial, Diabetes Obes Metab, 16, 334, 10.1111/dom.12221 Nelson, 2015, The support of human genetic evidence for approved drug indications, Nature Genetics, 47, 856, 10.1038/ng.3314 Freedman, 2003, Schizophrenia, N Engl J Med, 349, 1738, 10.1056/NEJMra035458 Lieberman, 2005, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia, New Engl J Med, 353, 1209, 10.1056/NEJMoa051688 Zhang, 2011, Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction, Expert Opin Drug Metab Toxicol, 7, 9, 10.1517/17425255.2011.532787 Holohan, 2013, Cancer drug resistance: an evolving paradigm, Nat Rev Cancer, 13, 714, 10.1038/nrc3599 Ripke, 2013, Genome-wide association analysis identifies 13 new risk loci for schizophrenia, Nat Genet, 45, 1150, 10.1038/ng.2742 Lichtenstein, 2006, Recurrence risks for schizophrenia in a Swedish national cohort, Psychol Med, 36, 1417, 10.1017/S0033291706008385 Suzuki, 2011, Treatment resistant schizophrenia and response to antipsychotics: a review, Schizophr Res, 133, 54, 10.1016/j.schres.2011.09.016 Zhang, 2013, Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia, Schizophr Res, 146, 285, 10.1016/j.schres.2013.01.020 Wettermark, 2007, The new Swedish Prescribed Drug Register—opportunities for pharmacoepidemiological research and experience from the first six months, Pharmacoepidemiol Drug Saf, 16, 726, 10.1002/pds.1294 Law, 2014, DrugBank 4·0: shedding new light on drug metabolism, Nucleic Acid Res, 42, D1091, 10.1093/nar/gkt1068 Keiser, 2009, Predicting new molecular targets for known drugs, Nature, 462, 175, 10.1038/nature08506 Keiser, 2007, Relating protein pharmacology by ligand chemistry, Nat Biotechnol, 25, 197, 10.1038/nbt1284 Whirl-Carrillo, 2012, Pharmacogenomics knowledge for personalized medicine, Clin Pharmacol Ther, 92, 414, 10.1038/clpt.2012.96 Nebert, 2002, Clinical importance of the cytochromes P450, Lancet, 360, 1155, 10.1016/S0140-6736(02)11203-7 Gordon, 2014, Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset, Hum Mol Gen, 23, 1957, 10.1093/hmg/ddt588 Lee, 2012, INRICH: interval-based enrichment analysis for genome-wide association studies, Bioinformatics, 28, 1797, 10.1093/bioinformatics/bts191 Kang, 2011, Spatio-temporal transcriptome of the human brain, Nature, 478, 483, 10.1038/nature10523 Darnell, 2001, Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function, Cell, 107, 489, 10.1016/S0092-8674(01)00566-9 Kennedy, 2014, The social and economic burden of treatment-resistant schizophrenia: a systematic literature review, Int Clin Psychopharmacol, 29, 63, 10.1097/YIC.0b013e32836508e6 Torrey, 2007, Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis, Schizophr Bull, 33, 729, 10.1093/schbul/sbl050 Pearson, 1982, Lethal effect of phenothiazine neuroleptics on the pathogenic protozoan Leishmania donovani, Science, 217, 369, 10.1126/science.6124040 Fond, 2014, Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate, Eur Arch Psychiatry Clin Neurosci, 264, 179, 10.1007/s00406-013-0413-4